Back to Clinical Trials Overview

Back To Cancer Clinical Trials

Your search for "Liver" returned 7 results:


A Phase Ib Dose Escalation Study of OMP-54F28 in Combination with Sorafenib in Patients with Hepatocellular Carcinoma
Principal Investigator(s): Celina Ang

A Multicenter, randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Levantinib (E7080) versus Sorafenib in First Line Treatment of Subjects with Unresectable Hepatocellular Carcinoma
Principal Investigator(s): Max W Sung

A Prospective Randomized Clinical Trial on 90Yttrium Trans-Arterial Radio-Embolization (Therasphere®) vs. Standard Of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT)
Principal Investigator(s): Dr. Myron Schwartz

A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in patients with RAS mutant Hepatocellular Carcinoma (HCC)
Principal Investigator(s): Celina Ang

Phase 3 Prospective, Randomized, Blinded And Controlled Investigation Of Hepasphere/Quadrasphere Microspheres For Delivery Of Doxorubicin For The Treatment Of Hepatocellular Cancer
Principal Investigator(s): Edward Kim

Coiling the GDA vs. Surefire During Y90 Infusion: The COSY Trial
Principal Investigator(s): Aaron Fischman

A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib
Principal Investigator(s): Myron Schwartz